Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS

Core Viewpoint - Analysts forecast Merck (MRK) to report quarterly earnings of $2.01 per share, reflecting a year-over-year increase of 43.6%, with revenues expected to reach $15.34 billion, a 5.9% increase compared to the previous year [1] Group 1: Earnings and Revenue Estimates - The consensus EPS estimate has been revised upward by 7% over the last 30 days, indicating analysts' reassessment of their initial forecasts [1] - The anticipated quarterly earnings of $2.01 per share and revenues of $15.34 billion highlight positive growth expectations for Merck [1] Group 2: Specific Sales Projections - Analysts project 'Sales- Oncology- Alliance revenue- Reblozyl' at $68.77 million, a year-over-year increase of 59.9% [2] - The consensus estimate for 'Sales- Vaccines- Pneumovax' is $70.63 million, indicating a decline of 26.4% from the prior year [2] - 'Sales- Vaccines- ProQuar/M-M-R II/Varivax' is estimated at $544.16 million, reflecting a 3.1% increase year over year [2] Group 3: Additional Sales Metrics - 'Sales- Alliance revenue- Lenvima' is expected to reach $265.43 million, showing a year-over-year increase of 14.4% [3] - 'Sales- Hospital Acute Care- Bridion - U.S.' is projected at $301.76 million, indicating a 9.3% increase from the previous year [3] - 'Sales- Oncology- Keytruda - U.S.' is anticipated to be $4.12 billion, reflecting an 18.2% increase year over year [3] Group 4: Animal Health and Vaccine Sales - 'Sales- Animal health - International' is forecasted at $1.05 billion, a 4.2% increase from the prior year [4] - 'Sales- Animal health - U.S.' is expected to be $495.47 million, indicating a 2.8% year-over-year increase [4] - 'Sales- Vaccines- Pneumovax - U.S.' is projected at $28.41 million, reflecting a decline of 29% from the previous year [4] Group 5: Market Performance - Over the past month, Merck shares have returned +1.6%, contrasting with the Zacks S&P 500 composite's -4% change [4]